TY - JOUR
T1 - Cancer Immunosurveillance and Immunoediting
T2 - The Roles of Immunity in Suppressing Tumor Development and Shaping Tumor Immunogenicity
AU - Smyth, Mark J.
AU - Dunn, Gavin P.
AU - Schreiber, Robert D.
N1 - Funding Information:
This review is dedicated to Dr. Lloyd J. Old on the occasion of his retirement as Scientific Director of the Ludwig Institute for Cancer Research. Lloyd Old has been a constant source of inspiration, information, encouragement and support to the field of tumor immunology in general and to the authors of this review in particular. The authors also wish to acknowledge the particularly helpful contributions of science and discussion that Dr. Yoshohiro Hayakawa made to this review. We are grateful to many individuals who have either been members of our laboratories or our close collaborators during the past 5 years who made significant contributions to the field including: Drs. Jack Bui, Ruby Chan, Erika Cretney, Mark Diamond, Hiroaki Ikeda, Catherine Koebel, Joseph Trapani, Jeremy Swann, Vijay Shankaran, Kathleen C.F. Sheehan, and Ravi Uppaluri. Work performed in the MJS laboratory was supported by grants from the National Health and Medical Research Council of Australia, cancer Council of Victoria and the National Cancer Institute, NIH (CA106377). Work in the RDS laboratory was supported by grants from the National Cancer Institute (CA43059 and CA 107527), The Ludwig Institute for Cancer Research, The Cancer Research Institute, and The Susan G. Komen Breast Cancer Foundation.
PY - 2006
Y1 - 2006
N2 - Cellular transformation and tumor development result from an accumulation of mutational and epigenetic changes that alter normal cell growth and survival pathways. For the last 100 years, there has been a vigorous debate as to whether the unmanipulated immune system can detect and eliminate such altered host derived cells despite the fact that cancer cells frequently express either abnormal proteins or abnormal levels of normal cellular proteins that function as tumor antigens. In this review, we discuss the current state of this argument and point out some of the recent key experiments demonstrating that immunity not only protects the host from cancer development (i.e., provides a cancer immunosurveillance function) but also can promote tumor growth, sometimes by generating more aggressive tumors. The terminology "cancer immunoediting" has been used to describe this dual host protective and tumor promoting action of immunity, and herein we summarize the ever-increasing experimental and clinical data that support the validity of this concept.
AB - Cellular transformation and tumor development result from an accumulation of mutational and epigenetic changes that alter normal cell growth and survival pathways. For the last 100 years, there has been a vigorous debate as to whether the unmanipulated immune system can detect and eliminate such altered host derived cells despite the fact that cancer cells frequently express either abnormal proteins or abnormal levels of normal cellular proteins that function as tumor antigens. In this review, we discuss the current state of this argument and point out some of the recent key experiments demonstrating that immunity not only protects the host from cancer development (i.e., provides a cancer immunosurveillance function) but also can promote tumor growth, sometimes by generating more aggressive tumors. The terminology "cancer immunoediting" has been used to describe this dual host protective and tumor promoting action of immunity, and herein we summarize the ever-increasing experimental and clinical data that support the validity of this concept.
UR - http://www.scopus.com/inward/record.url?scp=33646755569&partnerID=8YFLogxK
U2 - 10.1016/S0065-2776(06)90001-7
DO - 10.1016/S0065-2776(06)90001-7
M3 - Review article
C2 - 16730260
AN - SCOPUS:33646755569
SN - 0065-2776
VL - 90
SP - 1
EP - 50
JO - Advances in Immunology
JF - Advances in Immunology
ER -